We speculate that prostate cancer cells produce androgens (AR) in the tumor microenvironment, and that MetS may lead to early activation of AR.At the mCRPC stage, tumor cells are still androgen-dependent, and after ADT or chemotherapy, prostate cancer cells become more sensitive to trace amounts of androgens, thus accelerating tumor progression and leading to a shorter survival time for patients. The gene discussed is AR; the disease is prostate carcinoma.